DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.

Slides:



Advertisements
Similar presentations
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Advertisements

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
Alere TM HIV Combo Yuko Tamanoue, Product Development Department.
R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.
TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.
BioLife Plasma Services Experience with HBV NAT Testing
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
Antibody Screening / Detection & Antibody Identification
Poor Reproducibility of HIV­1 Low-level Viraemia Results with 3 Commercial Real-time PCR Assays Jean Ruelle 1, Laurent Debaisieux 2, Ellen Vancutsem 3,
Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
Qualification Panels for West Nile Virus RNA Tests Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA SoGAT Langen, Germany July 3, 2003.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.
Test 1Test 2Test 3Test 4Test 5Test 6 Sensitivity Specificity PPV NPV Performance.
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager.
Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
Phar. Nhat Mang/ Roche Vietnam
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.
BioPlex 2200 HIV Ag-Ab Assay
RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.
Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):
COMPARISON OF LABORATORY DIAGNOSTIC PROCEDURES FOR DETECTION OF MYCOPLASMA PNEUMONIAE IN COMMUNITY OUTBREAKS KATHLEEN A. THURMAN, NICHOLAS D. WALTER, STEPHANIE.
HBV viral load 측정 및 임상적 의의 진단검사의학과이희주 Content v 임상적 의의 v 측정법.
Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.
Global Rapid Diagnostic Leader SD. 2 HIV-2 positive HIV-1 positive 1 drop of blood (Simple) Wait in 1~5 Min. (Fast) Interpret the result visually (Accurate)
Cepheid Symposium IAS 2017 Gwynn Stevens, PhD Director of Virology
Chief, Laboratory of Molecular Virology, CBER, FDA
Abbott HCV core Ag and HCV RNA Comparison Study
Do Patients adherent on PrEP exposed to HIV have seroconversion symptoms & falsely reactive HIV tests? Mark Roche1, Elaney Youssef1, Yvonne Gilleece¹,
Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)
San Francisco Department of Public Health
Update on CBER HIV-1 Subtype panel
مدیریت امور آزمایشگاهها دانشگاه علوم پزشکی کاشان
Trust is good, control is better!
Challenges for Blood Donor Confirmatory Testing Algorithms
Presentation transcript:

DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories Diagnostics Division BPAC Meeting September 14, 2000

To develop more sensitive HIV antigen assays Short term: Comparable sensitivity to pooled NAT testing Long term: Sensitivity equivalent to single unit NAT testing OBJECTIVE

SENSITIVITY OF RESEARCH PRISM HIV Ag VS. CURRENT HIV ANTIGEN ASSAY ASSAYp24 ANTIGEN Dilution of pg/ml (est.) Research PrismHIV Ag 1-2 Estimated RNA copies/ml 1x x10 4 1: : x x HIVAG-1MC pg = 1x10 4 copies/ml

Comparison Between Sensitive HIV Antigen Testing and NAT Sensitivity of antigen assay is ~1.0 pg or ~10,000 copies of viral RNA Even at a claimed 50 copies/ml sensitivity for NAT: - a sample must have at least 4800 copies of viral RNA/ml to be detected in a pool of 96, or - 60,000 copies of viral RNA/ml in a pool of 1200

PANEL/BLEED #ABBOTTResearchNAT (copies/ml) a Dilution of HIVAG-1MC a PRISM AG c RocheNGIbDNA1:961:1200 S/CO b S/CO SV-0251/D SV-0321/A PRB-941/ PRB-943/ PRB-945/ /20875/17 BCP-9013/ BCP-6240/ BCP-9016/ EARLY SEROCONVERSION SAMPLES: COMPARISON OF POOLED NAT VS. HIV ANTIGEN TESTING a Data obtained from panel information sheets b S/CO > 1.00 is reactive c Research data

Advantages of Individual HIV Antigen Testing vs Pooled NAT Testing Fully automated system for antigen testing Rapid test results Process controls for enhanced GMP compliance No sample preparation/contamination issues Ability to confirm using neutralization test Simplicity for implementation No pools to dilute sensitivity No dissection of pools No shipping of specimens

Gap between individual antigen testing using a sensitive assay for HIV antigen and NAT of pooled samples may not be significant As opposed to discontinuation: Manufacturers should be encouraged to develop ultra-sensitive HIV antigen assays with sensitivities equal to or greater than single unit NAT CONCLUSIONS